- The Singapore Heart Lesion Analyser, called Sense, will be tested at three hospitals in Singapore starting Q3 2025 for heart scan analysis.
- The one-year trial will involve 300 patients and aims to reduce coronary artery disease assessment time from hours to under 10 minutes.
- Sense supports, rather than replaces, doctors’ clinical decisions, requiring their review and confirmation of the AI’s findings.
- The system has demonstrated 85% to 99% accuracy in earlier tests and could significantly impact early diagnosis of coronary artery disease, which caused 8,311 deaths in Singapore in 2023.
- Developed by the CVS.AI lab at NHCS, Sense builds on previous AI work using a large dataset from CT scans to improve speed and accuracy in heart problem detection.